Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. (PIRS) on August 10, 2020. The filing discloses the entry into a Material Definitive Agreement with Eli Lilly and Company ("Lilly") regarding a clinical trial collaboration.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a strategic partnership agreement rather than financial performance data.
Material Changes and Agreements
On August 10, 2020, Pieris entered into a non-exclusive Clinical Trial Collaboration and Supply Agreement with Lilly. Key terms include:
- Study Objective: A Phase 2 Clinical Study to evaluate the safety and efficacy of Pieris' PRS-343 in combination with ramucirumab (Cyramza) and paclitaxel for the second-line treatment of HER2+ advanced or metastatic gastric cancer.
- Roles: Pieris will sponsor the Study. Lilly will supply ramucirumab and provide input on clinical and regulatory aspects.
- Intellectual Property: Both parties will jointly own clinical data and inventions arising from the combination regimen.
- Control: Material changes to the protocol or ramucirumab usage require Lilly's prior written consent.
- Termination: The agreement may be terminated for material breach, patient safety concerns, regulatory actions, or discontinuation of compound development.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The primary risk disclosed relates to the termination clauses, specifically regarding patient safety issues or regulatory actions preventing the use of the compounds. The full agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2020.
Investor Verification Checklist
- Verify the full text of the Clinical Trial Collaboration and Supply Agreement when filed as an exhibit to the Q3 2020 Form 10-Q.
- Review the attached Press Release (Exhibit 99.1) for additional details on the strategic rationale.
- Monitor future filings for updates on the Phase 2 Study enrollment and preliminary safety data.
- Confirm the specific financial implications of the collaboration, as no upfront payments or milestone details are listed in this 8-K summary.